Opinion

Video

PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients

Elias Jabbour, MD, discusses findings from the PhALLCON trial relevant to treatment decisions for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.

Dr Jabbour discussed recent phase 3 PhALLCON trial (NCT03589326) data, supporting more potent third-generation tyrosine kinase inhibitor (TKI) ponatinib’s move to the frontline for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Adding ponatinib up front doubled minimal residual disease negativity complete response rates vs standard second-generation TKIs, meeting the primary end point. More patients avoided transplant, with improved event-free survival. Manageable cardiovascular risk was shown with dose adjustment. Dr McCloskey addressed challenges in Ph+ ALL and said selecting optimal TKI therapy is still based on patient factors, but ponatinib’s early activity and favorable safety support its use earlier in therapy to improve outcomes.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
2 experts in this video
Dr Sundar Jagannath
1 expert in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo